CROI 2019 Abstract eBook

Abstract eBook

Poster Abstracts

2005 UPDATE ON HIV CURE

Katharine J. Bar , University of Pennsylvania, Philadelphia, PA, USA Dr Bar will review our current understanding of HIV persistence, highlight major obstacles to HIV cure strategies, and discuss pre-clinical and clinical developments in the pursuit of functional or eradicative HIV cure. Please see the session overview for the Program Committee Workshop for New Investigators and Trainees for a description of the session. Sven Pischke , University Hospital Hamburg–Eppendorf, Hamburg, Germany Dr Pischke will discuss the clinical challenges with the treatment of patients with hepatitis E. Please see the overview for the Interactive Case-Based Workshop on Hepatitis for a full description of the session. Jeffrey Glenn , Stanford University, Stanford, CA, USA Dr Glenn will discuss the clinical challenges in treating patients with hepatitis D. Please see the overview for the Interactive Case-Based Workshop on Hepatitis for a full description of the session. Giada Sebastiani , McGill University Health Centre Research Institute, Montreal, QC, Canada Nonalcoholic fatty liver disease has become the most frequent liver disease in the aging HIV-infected population, with a prevalence at 35%. Its severe form, nonalcoholic steatohepatitis (NASH), is found in 65% of HIV mono-infected patients with chronic elevation of transaminases, which is a frequent occurrence in the practice of HIV medicine. A complex multifactorial pathogenesis, including frequent metabolic comorbidities, lifelong use of antiretroviral therapy and HIV itself, is thought to drive this epidemic. Early diagnosis, preventive and therapeutic strategies may help reduce the burden of NASH in people living with HIV.

2006 HEPATITIS E: CLINICAL CHALLENGES

2007 HEPATITIS D: CLINICAL CHALLENGES

2001 UPDATE ON HIV VIROLOGY

2008 NASH IN HIV

Paul Bieniasz , The Rockefeller University, New York, NY, USA Dr Bieniasz will review aspects of the HIV-1 replication cycle. In particular he will discuss recent developments in the understanding of virus entry, capsid function and RNA turnover. Penelope L. Moore , University of the Witwatersrand, Johannesburg, South Africa Dr Moore will describe advances in eliciting protective antibodies by vaccination, highlight emerging insights at the interface between innate and adaptive immunity, and summarize key new immunological findings at CROI. Please see the session overview for the Program Committee Workshop for New Investigators and Trainees for a description of the session. Sharon L. Hillier , Magee–Womens Hospital of UPMC, Pittsburgh, PA, USA Dr Hillier will describe the current landscape of biomedical HIV prevention research including vaccines, broadly neutralizing antibodies, oral and injectable pre-exposure prophylaxis, vaginal and rectal microbicides, and combination approaches for prevention of HIV. Please see the session overview for the Program Committee Workshop for New Investigators and Trainees for a description of the session. Constance A. Benson , University of California San Diego, San Diego, CA, USA Dr Benson will briefly summarize the current state-of-the-art for tuberculosis treatment and prevention, highlight recent new data in the field, including new information to be presented at CROI, and discuss research gaps in current knowledge that might generate new research in the field. Please see the session overview for the Program Committee Workshop for New Investigators and Trainees for a description of the session.

2002 UPDATE ON HIV IMMUNOLOGY

Poster Abstracts

2003 UPDATE ON HIV PREVENTION

2009 RETREATMENT OF HCV IN ADVANCED LIVER DISEASE John D. Scott , University of Washington, Seattle, WA, USA

Dr Scott will discuss the retreatment of HCV in patients with advanced liver disease. Please see the overview for the Interactive Case-Based Workshop on Hepatitis for a full description of the session.

2004 UPDATE ON TUBERCULOSIS TREATMENT AND PREVENTION

CROI 2019 431